Topline data from the Phase 3 STELLAR-4 trial showed that selonsertib, an investigational treatment for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), was not associated with a significant improvement in fibrosis without worsening of NASH.
Most Americans are concerned about their weight and understand the connection between weight and cardiovascular health, but a substantial proportion of them are not doing much to lose excess weight.
Few adolescents meet sleep, physical activity, and screen-time guidelines concurrently.
Investigators examined a link between major cardiovascular risk factors, such as older age and smoking, and venous thromboembolism, consisting of deep vein thrombosis or pulmonary embolism.
Both relative muscle strength and physical performance improved substantially in patients following Roux-en-Y gastric bypass surgery.
An inverse dose-dependent association exists between cardiorespiratory fitness and type 2 diabetes risk.
Self-reported weight history by ethnically diverse middle-aged to older patients is independently provides prognostic information about future heart failure risk.
Children with normal timing of BMI peak who experienced an early adiposity rebound or without any BMI decline after infancy appear to have the highest risk of developing an adverse cardiometabolic profile in adolescence.
Use of SGLT2 inhibitor dapagliflozin did not attenuate or augment any beneficial physiologic adaptations from endurance exercise training in overweight or obese adults.
Metabolically healthy and unhealthy obesity increase atrial fibrillation risk at a similar rate.
